In vitro activity and fecal concentration of rifaximin after oral administration

被引：132

作者：

Jiang, ZD

Ke, S

Palazzini, E

Riopel, L

Dupont, H

机构：

[1] Univ Texas, Ctr Infect Dis, Sch Publ Hlth, Houston, TX 77030 USA

[2] Univ Texas, Sch Med, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] St Lukes Episcopal Hosp, Houston, TX 77030 USA

[5] Baylor Coll Med, Houston, TX 77030 USA

[6] Alfa Wassermann SpA, Bologna, Italy

[7] Salix Pharmaceut Inc, Palo Alto, CA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 08期

关键词：

D O I：

10.1128/AAC.44.8.2205-2206.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Rifaximin showed moderately high MICs (the MIC at which 90% of the isolates tested were inhibited = 50 mu g/ml) for 145 bacterial enteropathogens from patients with traveler's diarrhea acquired in Mexico during the summers of 1997 and 1998, Rifaximin concentrations in stool the day after oral administration (800 mg daily for 3 days) were high (average, 7,961 mu g/g), proving the value of the drug.

引用

收藏

页码：2205 / 2206

页数：2

相关论文

共 13 条

[1] TREATMENT OF SMALL-INTESTINE BACTERIAL OVERGROWTH WITH RIFAXIMIN, A NON-ABSORBABLE RIFAMYCIN [J].

CORAZZA, GR ;

VENTRUCCI, M ;

STROCCHI, A ;

SORGE, M ;

PRANZO, L ;

PEZZILLI, R ;

GASBARRINI, G .

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1988, 16 (04) :312-316

[2]

DESCOMBE JJ, 1994, INT J CLIN PHARM RES, V14, P51

[3] TREATMENT OF TRAVELERS DIARRHEA WITH TRIMETHOPRIM SULFAMETHOXAZOLE AND WITH TRIMETHOPRIM ALONE [J].

DUPONT, HL ;

REVES, RR ;

GALINDO, E ;

SULLIVAN, PS ;

WOOD, LV ;

MENDIOLA, JG .

NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (14) :841-844

[4]

DUPONT HL, 1993, NEW ENGL J MED, V328, P1821, DOI 10.1056/NEJM199306243282507

[5] Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers' diarrhea [J].

DuPont, HL ;

Ericsson, CD ;

Mathewson, JJ ;

Palazzini, E ;

DuPont, MW ;

Jiang, ZD ;

Mosavi, A ;

de la Cabada, FJ .

DIGESTION, 1998, 59 (06) :708-714

[6] RIFAXIMIN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL IN CONDITIONS MEDIATED BY GASTROINTESTINAL BACTERIA [J].

GILLIS, JC ;

BROGDEN, RN .

DRUGS, 1995, 49 (03) :467-484

[7]

Gionchetti P, 1999, DIGEST DIS SCI, V44, P1220

[8] ANTIMICROBIAL ACTIVITY AND SPECTRUM OF RIFAXIMIN, A NEW TOPICAL RIFAMYCIN DERIVATIVE [J].

HOOVER, WW ;

GERLACH, EH ;

HOBAN, DJ ;

ELIOPOULOS, GM ;

PFALLER, MA ;

JONES, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1993, 16 (02) :111-118

[9] Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial [J].

Miglio, F ;

Valpiani, D ;

Rossellini, SR ;

Ferrieri, A .

CURRENT MEDICAL RESEARCH AND OPINION, 1997, 13 (10) :593-601

[10]

National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE